公司资料
Celcuity 股价、新闻与催化剂
- 股票代码:
- CELC
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
92.44 USD (+0.48%)
收盘价
最后更新: 2026年8月17日
4.46B USD
市值
股价为何变动
As of Aug 17, 2026, CELC closed up 0.48% at $92.44. No new same-company headline was identified in the current news window.
公司概览
PAM Pathway Oncology
Celcuity develops targeted therapies that inhibit the PI3K-AKT-mTOR signaling network, a pathway frequently involved in treatment resistance and tumor growth.
REVTORPYK
REVTORPYK, or gedatolisib, is an FDA-approved pan-PI3K and mTORC1/2 inhibitor for certain patients with hormone-receptor-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.
VIKTORIA-1
The Phase 3 VIKTORIA-1 program evaluates gedatolisib combinations after progression on endocrine therapy. Positive results in both PIK3CA wild-type and mutant cohorts support expansion of the approved population.
First-Line Development
VIKTORIA-2 evaluates gedatolisib regimens in the first-line advanced breast-cancer setting, including endocrine-sensitive and endocrine-resistant patient populations.
未来催化剂
- Submission of an sNDA for REVTORPYK in PIK3CA-mutant advanced breast cancer in the third quarter of 2026.
- Commercial launch of REVTORPYK in late third-quarter 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。